FLYNN JAMES E purchased 413.9% of their position (5M shares) of LARIMAR THERAPEUTICS, INC. on the open market
Open‑market purchase worth $25.00M — a major conviction buy. The strongest form of insider conviction signal.
P · 4 purchases
Filed: 3/2/2026ACC: 0001193805-26-000205
Director10% OwnerOther
Since May 2020
+5M
Net shares
Net buyer
$25.00M
Total acquired
4
Open market trades
4B · 0S
4
Total transactions
5M acquired
Non-Derivative Transactions4
Common Stock
Indirect
Shares
+1.08M
Price / share
$5.00
Trade value
$5.42M
% of position
11.4%
2/27/2026
9.54M→10.62M
Common Stock
Indirect
Shares
+1.08M
Price / share
$5.00
Trade value
$5.42M
% of position
11.4%
2/27/2026
9.54M→10.62M
Common Stock
Indirect
Shares
+831.98K
Price / share
$5.00
Trade value
$4.16M
% of position
11.4%
2/27/2026
7.32M→8.15M
Common Stock
Indirect
Shares
+2M
Price / share
$5.00
Trade value
$10M
% of position
47.5%
2/27/2026
4.21M→6.21M
Total
Net shares
+5M
Net value
$25M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 2/27/2026 | P · Purchase | +1.08M | $5.00 | $5.42M | 11.4% | 9.54M | 10.62M |
| Common Stock Indirect | 2/27/2026 | P · Purchase | +1.08M | $5.00 | $5.42M | 11.4% | 9.54M | 10.62M |
| Common Stock Indirect | 2/27/2026 | P · Purchase | +831.98K | $5.00 | $4.16M | 11.4% | 7.32M | 8.15M |
| Common Stock Indirect | 2/27/2026 | P · Purchase | +2M | $5.00 | $10M | 47.5% | 4.21M | 6.21M |
| Total | +5M | $25M | ||||||
Derivative Transactions0
No derivative transactions reported